Evidence map›Paper›PMID 36155523›Full record

ArticleJournal of Alzheimer's disease : JAD2022

Quality of Life and the Experience of Living with Early-Stage Alzheimer's Disease.

Alberto Villarejo-Galende, Elena García-Arcelay, Gerard Piñol-Ripoll, Antonio Del Olmo-Rodríguez, Félix Viñuela, Mercè Boada, Emilio Franco-Macías, Almudena Ibañez de la Peña, Mario Riverol, Albert Puig-Pijoan and 14 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 17 institutions in 1 country.

Alberto Villarejo-GalendeDepartment of Neurology, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain.
Elena García-ArcelayMedical Department, Roche Farma, Madrid, Spain.
Gerard Piñol-RipollCognitive Disorders Unit, Hospital Universitari Santa Maria de Lleida, Institut de Recerca Biomédica de Lleida (IRBLLeida), Lleida, Spain.
Antonio Del Olmo-RodríguezDepartment of Neurology, Hospital Universitario Dr. Peset, Valencia, Spain.
Félix ViñuelaInstituto Neurológico Andaluz, Hospital Victoria Eugenia, Unidad Deterioro Cognitivo, Hospital Universitario Virgen Macarena, Sevilla, Spain.
Mercè BoadaNetworking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
Emilio Franco-MacíasDementia Unit, Department of Neurology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain.
Almudena Ibañez de la PeñaCentro de Investigación de Parkinson, Policlínica Guipúzcoa, San Sebastián, Spain.
Mario RiverolDepartment of Neurology, Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain.
Albert Puig-PijoanCognitive Impairment and Movement Disorders Unit, Department of Neurology, Hospital del Mar, Hospital Del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Pedro Abizanda-SolerDepartment of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
Rafael ArroyoDepartment of Neurology, Hospital Universitario Quirónsalud, Madrid, Spain.
Miquel Baquero-ToledoGrup d'Investigació en Malaltia d'Alzheimer, Department of Neurology, Hospital Universitari i Politècnic La Fe, Institut d'Investigació Sanitaria La Fe, Valencia, Spain.
Inmaculada Feria-VilarDepartment of Neurology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
Mircea BalasaAlzheimer's Disease and other Cognitive Disorders Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Ángel BerbelDepartment of Neurology, Hospital Central de la Cruz Roja, Madrid, Spain.
Eloy Rodríguez-RodríguezDepartment of Neurology, Hospital Universitario de Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain.
Alba Vieira-CamposDepartment of Neurology, Hospital Universitario de La Princesa, Madrid, Spain.
Guillermo García-RibasDepartment of Neurology, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain.
Silvia Rodrigo-HerreroDepartment of Neurology, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain.
Ángeles TerrancleMedical Department, Roche Farma, Madrid, Spain.
Daniel PrefasiMedical Department, Roche Farma, Madrid, Spain.
Alberto LleóNetworking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
Jorge MaurinoMedical Department, Roche Farma, Madrid, Spain.
Roche (Spain) · ESInstituto de Salud Carlos III · ESComplejo Hospitalario Universitario de Albacete · ESResearch Institute Hospital 12 de Octubre · ESClinica Universidad de Navarra · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESHospital Central de la Cruz Roja San José y Santa Adela · ESHospital Del Mar · ESHospital Universitari de Santa Maria · ESHospital Universitari i Politècnic La Fe · ESHospital Universitario de La Princesa · ESHospital Universitario Doctor Peset · ESHospital Universitario Quirónsalud Madrid · ESHospital Universitario Virgen Macarena · ESInstituto de Biomedicina de Sevilla · ESPoliclínica Gipuzkoa · ESUniversidad de Cantabria · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is a need to better understand the experience of patients living with Alzheimer's disease (AD) in the early stages.

objectiveThe aim of the study was to evaluate the perception of quality of life in patients with early-stage AD.

methodsA multicenter, non-interventional study was conducted including patients of 50-90 years of age with prodromal or mild AD, a Mini-Mental State Examination (MMSE) score ≥22, and a Clinical Dementia Rating-Global score (CDR-GS) of 0.5.-1.0. The Quality of Life in Alzheimer 's Disease (QoL-AD) questionnaire was used to assess health-related quality of life. A battery of self-report instruments was used to evaluate different psychological and behavioral domains. Associations between the QoL-AD and other outcome measures were analyzed using Spearman's rank correlations.

resultsA total of 149 patients were included. Mean age (SD) was 72.3 (7.0) years and mean disease duration was 1.4 (1.8) years. Mean MMSE score was 24.6 (2.1). The mean QoL-AD score was 37.9 (4.5). Eighty-three percent (n = 124) of patients had moderate-to-severe hopelessness, 22.1% (n = 33) had depressive symptoms, and 36.9% (n = 55) felt stigmatized. The quality of life showed a significant positive correlation with self-efficacy and negative correlations with depression, emotional and practical consequences, stigma, and hopelessness.

conclusionStigma, depressive symptoms, and hopelessness are frequent scenarios in AD negatively impacting quality of life, even in a population with short disease duration and minimal cognitive impairment.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAgedHumansQuality of LifeSelf ReportSurveys and QuestionnairesAlzheimer’s diseaseamyloidbiomarkerscerebrospinal fluidmagnetic resonance imagingtau proteinswhite matter hyperintensitieswhite matter lesions

Identifiers

PMID36155523
PMCPMC9697050
OpenAlexW4297019144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.